New Age Alpha Advisors LLC Purchases New Stake in Artivion, Inc. (NYSE:AORT)

New Age Alpha Advisors LLC acquired a new position in Artivion, Inc. (NYSE:AORT - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 52,223 shares of the company's stock, valued at approximately $1,493,000. New Age Alpha Advisors LLC owned approximately 0.12% of Artivion as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares in the last quarter. Quarry LP grew its stake in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock valued at $32,000 after buying an additional 820 shares during the period. R Squared Ltd acquired a new stake in shares of Artivion during the 4th quarter worth $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion in the 4th quarter worth $43,000. Finally, Venturi Wealth Management LLC acquired a new position in Artivion in the fourth quarter valued at $78,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AORT has been the topic of a number of research reports. JMP Securities restated a "market outperform" rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Finally, Stifel Nicolaus reduced their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion presently has an average rating of "Buy" and an average price target of $31.40.

Insiders Place Their Bets

In related news, insider John E. Davis sold 6,457 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $176,340.67. Following the sale, the insider now directly owns 160,631 shares of the company's stock, valued at $4,386,832.61. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James P. Mackin sold 42,156 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the transaction, the chief executive officer now directly owns 663,882 shares of the company's stock, valued at approximately $18,130,617.42. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock worth $2,356,223 in the last quarter. 8.10% of the stock is owned by corporate insiders.

Artivion Stock Down 3.7 %

Shares of AORT stock traded down $0.90 during trading hours on Friday, reaching $23.24. The company had a trading volume of 712,090 shares, compared to its average volume of 281,697. The company has a market capitalization of $977.20 million, a P/E ratio of -1,162.00 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a twelve month low of $18.40 and a twelve month high of $32.33. The stock's fifty day simple moving average is $26.93 and its 200 day simple moving average is $27.59.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analysts' expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.